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Summary and Implications 
 The objective of this study was to test the 
effectiveness of Cystorelin™ (gonadorelin diacetate 
tetrahydrate) in inducing ovulation in cyclic mares.  
Mares were treated with either three 75 μg (1.5 mL) i.m. 
injections of Cystorelin™ or three 1.5 mL i.m. injections 
of sterile saline (control) given two hours apart. Blood 
samples were collected every 30 minutes to monitor LH 
concentrations.  No difference was observed in LH 
secretion patterns of control and treated mares.  Mares 
treated with Cystorelin™ ovulated 2.25 ± .25 days after 
treatment which was one day earlier (P<.05) than control 
mares (3.25 ± .41 days). Of the treatment mares, 71% 
(12/17) ovulated within 48 hours after treatment 
compared with 14% (1/7) of control mares.  Treatment 
and control mares were not different (P>.81), however, 
for variability in days to ovulation.  Treatment with 
Cystorelin™ effectively hastened ovulation in mares, 
which could prove useful for timed artificial insemination. 
Further research is necessary, however, to develop a 
protocol that can also reduce variability in the time of 
ovulation. 
 
Introduction 
 The mare is a domestic animal species with many 
reproductive challenges.  Mares are seasonal breeders, 
their estrous cycle lengths can be erratic, the length of the 
period of estrus is highly variable, and the timing of 
ovulation within the period of estrus is highly 
unpredictable. Collectively, these factors pose obstacles 
that can be difficult to overcome.    
 Having the ability to regulate the time of ovulation in 
the mare would be beneficial for many reasons, but 
especially for use with artificial insemination.  Precise 
control of the time of ovulation would increase 
management and labor efficiency, optimize the time of 
breeding when using transported semen, and reduce the 
number of times a mare is bred during a given estrous 
cycle.    
 Various exogenous hormones have been used in an 
attempt to regulate cyclicity in mares.  Although 
progesterone analogues and prostaglandin F2α (PGF) 
have been used to synchronize estrus, the response to 
these hormones has been variable and control of the time of 
ovulation has been inconsistent.  Two other exogenous 
hormones, human chorionic gonadotropin (hCG) and the 
GnRH analogue deslorelin, have been used to induce 
ovulation in the mare, but use of each has resulted in negative 
side effects.   
 The initial use of hCG to control the time of ovulation in 
mares can be successful; however, due to the antigenic nature 
of hCG, mares often become refractory to repeated treatments, 
rendering the product ineffective. The GnRH analogue 
deslorelin, when administered via an implant (Ovuplant™), 
has reportedly caused desensitization of the anterior pituitary 
gland to GnRH, resulting in suppressed gonadotropin 
secretion and an extended interval between induced ovulation 
and the subsequent ovulation if the mare does not become 
pregnant.  (This side effect is most prevalent when Ovuplant™ 
is left in place for over 48 hours.)  Ovuplant™ was withdrawn 
from the market and is no longer available.  The 
unpredictability and/or market unavailability of these 
ovulation-inducing hormones has led to demand for a reliable 
and readily available treatment for inducing ovulation in 
mares. 
 The cattle industry has many different GnRH products 
available to induce rupture of cystic ovarian follicles. These 
products have also been used in an extra-label manner to 
control the time of ovulation in timed artificial insemination 
protocols such as OvSynch.  To our knowledge, no one has 
tested the effectiveness of Cystorelin™ in controlling the time 
of ovulation in mares, and this experiment was designed to do 
so.   
 
Materials and Methods 
 A total of 24 Iowa State University mares was used in this 
study. Mares were of Thoroughbred (n=9) and stock type 
(Paint and Quarter Horse; n=15) breeding. The first trial (Trial 
A) was performed during the 2006 breeding season (May-
June) using 6 mares, and the second trial (Trial B) was 
performed during the 2007 breeding season (February-May) 
using 18 mares.  In both trials mares possessing an ovarian 
follicle 3.5 cm to 4.0 cm in diameter were randomly assigned 
to either treatment with three 75 μg (1.5 mL) i.m. injections of 
Cystorelin™ or three 1.5 mL i.m. injections of sterile saline 
(control) given two hours apart.  After the start of treatment, 
ultrasonography was performed daily until ovulation was 
confirmed. 
 Blood samples were collected from treatment and control 
mares via an indwelling jugular catheter. Blood was drawn 30 
minutes prior to, immediately prior to, and at 30-minute 
intervals after the initial injection (GnRH or saline) for six 
(Trial A) or 10 (Trial B) hours to measure luteinizing hormone 
(LH). In trial B, an additional blood sample was collected 
  
daily starting the day after treatment until ovulation was 
confirmed.  Luteinizing hormone was measured by 
radioimmunoassay. Intra-and inter-assay coefficients of 
variation and assay sensitivities were 6%, 9%, and 0.2 
ng/mL, respectively.  
 Data were analyzed using the GLM procedure of 
SAS for a completely randomized design (SAS Inst. Inc., 
Cary, NC) to test the effect of treatment and breed on 
days to ovulation and plasma LH levels. Levene’s test 
was used to analyze the variability in days to ovulation 
between treatment and control mares. 
 
Results 
 The effect of year was tested and found to be non 
significant (P>.57), so data were pooled across years. The 
diameter of the largest follicle at the time of treatment 
was not different (P>.42) between treatment (3.8 ± .03 
cm) and control (3.8 ± .06) mares. Mares treated with 
Cystorelin™ ovulated 2.25 ± .25 days after treatment 
which was one day earlier (P<.05) than control mares 
(3.25 ± .41). Of the treatment mares, 71% (12/17) 
ovulated within 48 hours after treatment compared with 
14% (1/7) of control mares (Table 1). Treatment and 
control mares were not different (P>.81) for variability in 
days to ovulation. 
 Mean plasma LH levels were calculated over four 
time periods (-30 to 0 min [Period 1 = baseline], 30-120 
min [Period 2], 150-240 min [Period 3], and 270-360 min 
[Period 4]). Luteinizing hormone response was analyzed 
by comparing the mean LH value of Periods 2, 3, and 4 
with the baseline mean (Figure 1). Although the 
concentration of LH in Period 2 [2.60 ng/ml] tended 
(P<.07) to be higher than baseline [1.97 ng/ml] in 
Cystorelin™-treated mares, elevations in plasma LH 
concentration in Periods 3 and 4 were not different in 
treatment versus control mares (P>.15 and P>.18 
respectively). 
 
Discussion 
 The reproductive status of treatment and control 
mares was not different, as evidenced by similar (3.8 cm) 
ovarian follicle diameters at the initiation of treatment.  
Our three-shot Cystorelin™ protocol was effective in 
hastening ovulation in mares by one full day. The 71% of 
mares that ovulated within 48 hours after treatment with 
Cystorelin™ is comparable to results reported by others 
who investigated the use of hCG or deslorelin 
BioRelease™ for control of the time of ovulation in 
mares.   
 Variability in days to ovulation was similar between 
Cystorelin™ treated and control mares (P>.81), despite 
the average earlier post-treatment onset of ovulation.  
This result was surprising but may be due to the relatively 
small number of experimental animals available for use in 
this study.  Clearly, a refinement in protocol is needed to 
obtain a more consistent and predictable interval from 
Cystorelin™ treatment to ovulation if this protocol is to be 
universally adopted in the equine breeding industry. 
 Luteinizing hormone secretion patterns were similar 
between control and treatment mares.  Although the LH 
release in response to treatment was not statistically higher 
than LH levels observed in control mares, there was a 
tendency (P<.07) for elevated LH level after the first 
Cystorelin™ treatment. This may explain why a higher 
proportion of Cystorelin™-treated mares ovulated within 48 
hours of treatment.  We were somewhat surprised at the lack 
of a significant and sustained increase in plasma LH level in 
response to Cystorelin™ treatment, but our results may be 
partially explained by the low dose of gonadorelin we 
administered, individual variation among mares, or the 
relatively small number of experimental animals used in our 
study.  Interestingly, inconsistencies in LH response have been 
previously reported by other researchers. 
 Data from this experiment suggest that Cystorelin™ could 
effectively be used in routine equine breeding management to 
hasten ovulation in mares. Although we did not specifically 
test this in our study, Cystorelin™ treatment potentially could 
be used to overcome problematic hCG antibody formation (as 
well as availability issues with deslorelin products). This 
treatment protocol is practical for horse breeders to use and 
only requires a veterinary prescription for Cystorelin™ use.  
This protocol is much more convenient that that for 
Ovuplant™ which typically required the services of a 
veterinarian to insert and remove the implant. Further studies 
with increased mare numbers need to be conducted to further 
refine this protocol, however, before recommending the 
widespread use of Cystorelin™ to control the time of 
ovulation in cyclic mares. 
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Table 1. Ovarian status and response to treatment with either Cystorelin™ or saline.  
 
Variable  Cystorelin™ 
mares  
Control mares  
 
Follicle size (cm) at initiation of 
treatment*  
 
3.8 ± .03  
 
3.8 ± .06  
 
Days from initiation of treatment to 
ovulation*  
 
2.25 ± .25
a
  
 
3.25 ± .41
b
  
 
 
Hours to ovulation (post treatment)                            Percent ovulated 
24  6% (1/17)  0% (0/7)  
48  65% (11/17)  14% (1/7)  
72  6% (1/17)  43% (3/7)  
≥96  12% (2/17)  43% (3/7)  
No ovulation  12% (2/17)  0% (0/7)  
 
  * Mean ± standard error of the mean (SEM) 
a,b
  Means with unlike superscripts differ (P<.05) 
 
 
 
Figure 1. Mean plasma LH increase over time between treatment and control mares. 
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